Search
Tag: biotech
A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer’s disease: Primary results of the AMBAR Study
This phase 2b/3 trial investigated the effects of plasma exchange (PE) with albumin replacement in patients with mild-to-moderate Alzheimer’s disease (AD). In the study,…
Read More
Plasma exchange for Alzheimer’s disease Management by Albumin Replacement (AMBAR) trial: Study design and progress
The AMBAR (Alzheimer Management By Albumin Replacement) study is a multicenter, randomized, placebo-controlled phase IIb/III trial investigating the effects of plasma exchange (PE) with…
Read More
Results of Grifols’ AMBAR clinical trial published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association
The results of Grifols’ AMBAR (Alzheimer Management by Albumin Replacement) clinical trial, published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, show…
Read More
Grifols AMBAR results demonstrate a significant reduction in the progression of moderate Alzheimer’s Disease
Grifols’ AMBAR (Alzheimer Management by Albumin Replacement) study results show that plasma exchange with albumin replacement significantly slows the progression of moderate Alzheimer’s disease….
Read More
Neuropsychological, neuropsychiatric, and quality-of-life assessments in Alzheimer’s disease patients treated with plasma exchange with albumin replacement from the randomized AMBAR study
The 2021 AMBAR (Alzheimer’s Management by Albumin Replacement) study investigated the effects of plasma exchange (PE) with albumin replacement on neuropsychological, neuropsychiatric, and quality-of-life…
Read More